Covid: First part of phase-1 Covaxin human trial completed at PGI Rohtak
The first part of phase-1 of Covaxin human trial completed on Saturday. The trial was conducted at Post-Graduate Institute (PGI) of Medical Sciences, Rohtak, said Dr Savita Verma, principal investigator of the vaccine trial team. Dr Verma said that six people were administered the vaccine on Saturday under the second part of phase-1. “First part of phase-1 of vaccine trial (Covaxin) has been completed. 50 people across India were administered the vaccine and the results were encouraging. Six people were administered vaccine on Saturday under second part of phase-1,” she said. Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were administered Covaxin on that day. Covid-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the approval for human clinical trials from the Drugs Controller General of India (DCGI). The total number of infections crossed 13 lakh in India and so far coronavirus has claimed lives of more than 31,000 people.